PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET
Armata Pharmaceuticals reported Q3 2026 GAAP net income of $54.9M ($1.15 basic EPS, $(0.24) diluted EPS), driven by a $69.6M non-cash gain from convertible loan fair value change. Operating loss narrowed to $7.4M from $7.8M a year ago. The company is preparing for a Phase 3 study of AP-SA02, which received FDA Breakthrough Therapy designation, and received $3.7M in non-dilutive DoW funding. Consensus EPS of $(0.56) was not met on a GAAP basis; the diluted loss per share of $(0.24) compares to a consensus estimate of $(0.56), representing a beat of 57.1%.